Skip to main content

Candel Therapeutics Inc(CADL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low6.39
Day High7.05
Open:7.04
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL)
Tipranks
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk
GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Candel Therapeutics Announces Equity Offering to Fund CAN-2409
GlobeNewswire
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
Tipranks
Candel Therapeutics Secures $100M Royalty Funding for CAN-2409
GlobeNewswire
Candel Therapeutics Announces Pricing of Public Offering
GlobeNewswire
Candel Therapeutics Announces Proposed $100 Million Public Offering
GlobeNewswire
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
GlobeNewswire
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
Tipranks
Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update
GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks Investment Research
New Strong Sell Stocks for January 20th
New Strong Sell Stocks for January 20th
Tipranks
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Stereotaxis (STXS)
Tipranks
Candel Therapeutics Hosts Virtual R&D Day on Immunotherapy
Tipranks
Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE)
Tipranks
Bank of America Securities Sticks to Their Hold Rating for Candel Therapeutics (CADL)
Tipranks
Candel Therapeutics Advances Cancer Therapies with Strong Q3
GlobeNewswire
Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
GlobeNewswire
Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London
Tipranks
Canaccord Genuity Sticks to Its Buy Rating for Candel Therapeutics (CADL)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Candel Therapeutics (CADL), Gain Therapeutics (GANX)
Tipranks
Candel Therapeutics announces interim data from phase 1b CAN-3110 trial
GlobeNewswire
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
GlobeNewswire
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
GlobeNewswire
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
GlobeNewswire
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Profile

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.